Literature DB >> 14643947

Opiate maintenance with buprenorphine in ambulatory care: a 24-week follow-up study of new users.

M Lapeyre-Mestre1, M-E Llau, M Gony, A-M Navel, J Bez, M Grau, J-L Montastruc.   

Abstract

BACKGROUND: Many studies suggest that buprenorphine, a long acting partial opioid agonist, may be comparable to methadone in efficacy, with fewer withdrawal symptoms and a lower risk of overdose. The aim of this study was to assess the patterns of buprenorphine prescription use in ambulatory care and retention rate under treatment during a 24-week follow-up period.
METHODS: This observational cohort study included buprenorphine users identified from the French Health System prescription database in an area of 1 million inhabitants and followed for 24 weeks.
RESULTS: We selected 282 users of buprenorphine defined as "new users" (74% male, mean age 32.4+/-6.2 years). Three groups were defined: 50% of "rational users" (141 subjects, no more than 2 prescribers), 24% of "occasional users" (67 subjects, less than 2 buprenorphine prescriptions) and 26% of "non-rational users" (74 subjects, 3 or more prescribers). The overall 24-week treatment retention rate was 37%. Misuse of buprenorphine or benzodiazepines was significantly more frequent in "non-rational" than "rational users".
CONCLUSION: The retention rate with buprenorphine estimated in this observational study was very similar to that obtained in controlled trials. A majority of regular users of buprenorphine could be regarded as "rational users" in this area of France.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14643947     DOI: 10.1016/j.drugalcdep.2003.08.005

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  7 in total

1.  Assessment of abuse potential of benzodiazepines from a prescription database using 'doctor shopping' as an indicator.

Authors:  Vincent Pradel; Catherine Delga; Frank Rouby; Joëlle Micallef; Maryse Lapeyre-Mestre
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

2.  Mortality Associated With Time in and Out of Buprenorphine Treatment in French Office-Based General Practice: A 7-Year Cohort Study.

Authors:  Julie Dupouy; Aurore Palmaro; Mélina Fatséas; Marc Auriacombe; Joëlle Micallef; Stéphane Oustric; Maryse Lapeyre-Mestre
Journal:  Ann Fam Med       Date:  2017-07       Impact factor: 5.166

3.  Novel forms of injectable buprenorphine and French model of opioid use disorder treatment.

Authors:  Maryse Lapeyre-Mestre
Journal:  Therapie       Date:  2020-09-28       Impact factor: 2.070

4.  Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey.

Authors:  Olivia Boeuf; Maryse Lapeyre-Mestre
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

5.  Prospective Study on Factors Associated with Referral of Patients with Opioid Maintenance Therapy from Specialized Addictive Disorders Centers to Primary Care.

Authors:  Morgane Guillou-Landreat; Philippe Levassor; Marylène Guerlais; Veronique Sebille; Caroline Victorri-Vigneau
Journal:  Int J Environ Res Public Health       Date:  2021-05-27       Impact factor: 3.390

Review 6.  Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance Network.

Authors:  Thomas Soeiro; Clémence Lacroix; Vincent Pradel; Maryse Lapeyre-Mestre; Joëlle Micallef
Journal:  Front Psychiatry       Date:  2021-05-17       Impact factor: 4.157

7.  Study protocol of the ESUB-MG cluster randomized trial: a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients.

Authors: 
Journal:  BMC Fam Pract       Date:  2016-03-01       Impact factor: 2.497

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.